Tìm theo
Mefenamic acid
Các tên gọi khác (13 ) :
  • Acide méfénamique
  • Acido mefenamico
  • Acidum mefenamicum
  • CI-473
  • CN 35355
  • CN-35355
  • INF 3355
  • INF-3355
  • Mefenaminsaeure
  • Mefenaminsäure
  • N-(2,3-Xylyl)-2-aminobenzoic acid
  • N-2,3-Xylylanthranilic acid
  • Ponstel
Thuốc giảm đau, hạ sốt, chống viêm không steroid, điều trị Gút và các bệnh xương khớp
Thuốc Gốc
Small Molecule
CAS: 61-68-7
ATC: M01AG01
ĐG : PD-Rx Pharmaceuticals Inc. , http://www.pdrx.com
CTHH: C15H15NO2
PTK: 241.2851
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase. [PubChem]
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C15H15NO2
Phân tử khối
241.2851
Monoisotopic mass
241.110278729
InChI
InChI=1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18)
InChI Key
InChIKey=HYYBABOKPJLUIN-UHFFFAOYSA-N
IUPAC Name
2-[(2,3-dimethylphenyl)amino]benzoic acid
Traditional IUPAC Name
mefenamic acid
SMILES
CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1
Độ tan chảy
230-231 °C
Độ hòa tan
20 mg/L (at 30 °C)
logP
5.12
logS
-3.78
pKa (strongest acidic)
3.89
pKa (Strongest Basic)
-1.6
PSA
49.33 Å2
Refractivity
71.88 m3·mol-1
Polarizability
26.22 Å3
Rotatable Bond Count
3
H Bond Acceptor Count
3
H Bond Donor Count
2
Physiological Charge
-1
Number of Rings
2
Bioavailability
1
Ghose Filter
true
pKa
4.2
Dược Lực Học : Mefenamic acid, an anthranilic acid derivative, is a member of the fenamate group of nonsteroidal anti-inflammatory drugs (NSAIDs). It exhibits anti-inflammatory, analgesic, and antipyretic activities. Similar to other NSAIDs, mefenamic acid inhibits prostaglandin synthetase.
Cơ Chế Tác Dụng : A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase. [PubChem] Mefenamic acid binds the prostaglandin synthetase receptors COX-1 and COX-2, inhibiting the action of prostaglandin synthetase. As these receptors have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity, the symptoms of pain are temporarily reduced.
Dược Động Học :
▧ Absorption :
Mefenamic acid is rapidly absorbed after oral administration.
▧ Volume of Distribution :
* 1.06 L/kg [Normal Healthy Adults (18-45 yr)]
▧ Protein binding :
90%
▧ Metabolism :
Mefenamic acid undergoes metabolism by CYP2C9 to 3-hydroxymethyl mefenamic acid, and further oxidation to a 3-carboxymefenamic acid may occur. The activity of these metabolites has not been studied. Mefenamic acid is also glucuronidated directly.
▧ Route of Elimination :
The fecal route of elimination accounts for up to 20% of the dose, mainly in the form of unconjugated 3-carboxymefenamic acid.3 The elimination half-life of mefenamic acid is approximately two hours. Mefenamic acid, its metabolites and conjugates are primarily excreted by the kidneys. Both renal and hepatic excretion are significant pathways of elimination.
▧ Half Life :
2 hours
▧ Clearance :
* Oral cl=21.23 L/hr [Healthy adults (18-45 yrs)]
Độc Tính : Oral, rat LD50: 740 mg/kg. Symptoms of overdose may include severe stomach pain, coffee ground-like vomit, dark stool, ringing in the ears, change in amount of urine, unusually fast or slow heartbeat, muscle weakness, slow or shallow breathing, confusion, severe headache or loss of consciousness.
Chỉ Định : For the treatment of rheumatoid arthritis, osteoarthritis, dysmenorrhea, and mild to moderate pain, inflammation, and fever.
Tương Tác Thuốc :
  • Acenocoumarol The NSAID, mefanamic acid, may increase the anticoagulant effect of acenocoumarol.
  • Alendronate Increased risk of gastric toxicity
  • Anisindione The NSAID, mefanamic acid, may increase the anticoagulant effect of anisindione.
  • Azilsartan medoxomil Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
  • Colesevelam Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
  • Cyclosporine Monitor for nephrotoxicity
  • Dicoumarol The NSAID, mefanamic acid, may increase the anticoagulant effect of dicumarol.
  • Eltrombopag Increases levels of Mefenamic acid via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
  • Lithium The NSAID, mefenamic acid, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
  • Methotrexate The NSAID, mefenamic acid, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
  • Tamoxifen Mefenamic acid may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Mefenamic acid is initiated, discontinued or dose changed.
  • Tolbutamide Mefanamic acid, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Mefanamic acid is initiated, discontinued or dose changed.
  • Torasemide Mefanamic acid, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Mefanamic acid is initiated, discontinued or dose changed.
  • Trandolapril The NSAID, Mefenamic acid, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Mefenamic acid is initiated, discontinued or dose changed.
  • Treprostinil The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Mefenamic acid. Monitor for increased bleeding during concomitant thearpy.
  • Trimethoprim The strong CYP2C9 inhibitor, Mefenamic acid, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Mefenamic acid is initiated, discontinued or dose changed.
  • Voriconazole Mefanamic acid, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if mefanamic acid is initiated, discontinued or dose changed.
  • Warfarin Mefenamic acid, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of mefenamic acid may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if mefenamic acid is initiated, discontinued or dose changed.
Liều Lượng & Cách Dùng : Capsule - Oral
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty : Parke Davis
    Sản phẩm biệt dược : Coslan
  • Công ty : SIT
    Sản phẩm biệt dược : Lysalgo
  • Công ty : SecFarm
    Sản phẩm biệt dược : Mefacit
  • Công ty : Pfizer
    Sản phẩm biệt dược : Parkemed
  • Công ty : Coronet Crown
    Sản phẩm biệt dược : Ponalar
  • Công ty : Pfizer
    Sản phẩm biệt dược : Ponstan
  • Công ty : Pfizer
    Sản phẩm biệt dược : Ponstan Forte
  • Sản phẩm biệt dược : Ponstel
  • Công ty : Pfizer
    Sản phẩm biệt dược : Ponstyl
  • Công ty : Pfizer
    Sản phẩm biệt dược : Ponstyl Fort
  • Công ty : Daiichi Sankyo
    Sản phẩm biệt dược : Pontal
  • Công ty : Pfizer
    Sản phẩm biệt dược : Tanston
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00784
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=4044
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46505405
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C02168
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D00151
ChemSpider
http://www.chemspider.com/Chemical-Structure.3904.html
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50134036
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0677-1934-01
PharmGKB
http://www.pharmgkb.org/drug/PA450347
Wikipedia
http://en.wikipedia.org/wiki/Mefenamic_acid
RxList
http://www.rxlist.com/cgi/generic3/mefenamic.htm
Drugs.com
http://www.drugs.com/cdi/mefenamic-acid.html
... loading
... loading